An interventional study of Diazepam in Alcohol Withdrawal, sponsored by Centre for Addiction and Mental Health. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Alcoholism by Centre for Addiction and Mental Health — 3 open to participants now, 4 under way, none of them phase 3. Alcoholism · Centre for Addiction and Mental Health.
Among the 22 studies in Alcoholism by Centre for Addiction and Mental Health, this one is the 17th largest by enrollment, is one of 3 that started in 2021, is one of 14 with no phase, and was the 13th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →3 of the 22 studies in Alcoholism by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–59
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 48 across the 22 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Alcoholism by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the feasibility of delivering symptom-triggered alcohol withdrawal management by telemedicine and determine whether this intervention is satisfactory to patients.
This single-arm pilot feasibility study will recruit actively drinking participants with a history of alcohol withdrawal in order to provide remotely monitored symptom-triggered alcohol withdrawal treatment using telemedicine. Participants will initially complete a screening and eligibility visit. If eligible, participants will then be scheduled for 3-day remote withdrawal management (which can be extended by 1-2 days if medically indicated). During remote withdrawal management, participants will receive symptom-triggered diazepam treatment using a modified version of the Clinical Institute Withdrawal Assessment for Alcohol Scale, revised (CIWA-Ar). Within one week following termination of withdrawal treatment, participants will be scheduled for a remote follow up visit in which they will complete patient satisfaction questionnaires and will be offered weekly counselling sessions and anticraving medication to prevent relapse to alcohol use. Approximately 30 days following treatment initiation, relapse to alcohol use will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
Drug: Diazepam
Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
Also known as: Valium
Retention in Treatment
Retention in treatment, as measured by the percentage of participants who complete the entire 3-day remote withdrawal management protocol.
Time frame: 3-5 day treatment period
Transfer to a Higher Level of Care
Transfer to a higher level of care, as measured by the percentage of participants sent to the emergency room due to complications, need for intensive monitoring, or acute intoxication. If ≤ 20%, of participants require transfer to a higher level of care, we will consider this as additional evidence of feasibility.
Time frame: 3-5 day treatment period
Patient Satisfaction With the Treatment Protocol
Satisfaction with the overall treatment protocol, measured with the Client Satisfaction Questionnaire-8 (minimum score = 8; maximum score = 32; higher score indicates greater client satisfaction).
Time frame: Measured within 1 week of completing the remote withdrawal procedure
Patient Satisfaction With the Telemedicine Platform
Satisfaction with the telemedicine platform, measured with a modified version of the Telehealth Satisfaction Scale (minimum score = 12; maximum score = 48; higher score indicates greater satisfaction with the telemedicine platform).
Time frame: Measured within 1 week of completing the remote withdrawal procedure
Duration of Active Withdrawal Treatment
Duration of active withdrawal treatment, as measured by the number of days that patients received diazepam among patients who received benzodiazepines.
Time frame: 3-5 day treatment period
Requirement of Benzodiazepines
Benzodiazepines requirement, as measured by the percentage of participants requiring benzodiazepine treatment.
Time frame: 3-5 day treatment period
Diazepam Dose
Diazepam dose, as measured by the average dose of diazepam required to control symptoms among patients who received diazepam.
Time frame: 3-5 day treatment period
Withdrawal Severity
Withdrawal severity, as measured by the average peak Clinical Institute Withdrawal Assessment for Alcohol Scale, revised score measured over the treatment period (minimum score = 0; maximum score = 67; higher score indicates greater withdrawal severity).
Time frame: 3-5 day treatment period
| Milestone | Symptom-triggered Diazepam Treatment |
|---|---|
| Started | 30 |
| Completed | 28 |
| Not completed | 2 |
| Withdrew: Relapse to alcohol during treatment | 2 |
Retention in treatment, as measured by the percentage of participants who complete the entire 3-day remote withdrawal management protocol.
| Participants | Symptom-triggered Diazepam Treatment |
|---|---|
| Retention in Treatment | 28 |
Transfer to a higher level of care, as measured by the percentage of participants sent to the emergency room due to complications, need for intensive monitoring, or acute intoxication. If ≤ 20%, of participants require transfer to a higher level of care, we will consider this as additional evidence of feasibility.
| Participants | Symptom-triggered Diazepam Treatment |
|---|---|
| Transfer to a Higher Level of Care | 0 |
Satisfaction with the overall treatment protocol, measured with the Client Satisfaction Questionnaire-8 (minimum score = 8; maximum score = 32; higher score indicates greater client satisfaction).
| Score on a scale | Symptom-triggered Diazepam Treatment |
|---|---|
| Patient Satisfaction With the Treatment Protocol | 30.9 ± 1.5 |
Satisfaction with the telemedicine platform, measured with a modified version of the Telehealth Satisfaction Scale (minimum score = 12; maximum score = 48; higher score indicates greater satisfaction with the telemedicine platform).
| Score on a scale | Symptom-triggered Diazepam Treatment |
|---|---|
| Patient Satisfaction With the Telemedicine Platform | 45.1 ± 2.5 |
Duration of active withdrawal treatment, as measured by the number of days that patients received diazepam among patients who received benzodiazepines.
| days | Symptom-triggered Diazepam Treatment |
|---|---|
| Duration of Active Withdrawal Treatment | 2.4 ± 0.7 |
Benzodiazepines requirement, as measured by the percentage of participants requiring benzodiazepine treatment.
| Participants | Symptom-triggered Diazepam Treatment |
|---|---|
| Requirement of Benzodiazepines | 27 |
Diazepam dose, as measured by the average dose of diazepam required to control symptoms among patients who received diazepam.
| mg | Symptom-triggered Diazepam Treatment |
|---|---|
| Day 1 | 30 (10 to 50) |
| Day 2 | 20 (0 to 40) |
| Day 3 | 10 (0 to 20) |
Withdrawal severity, as measured by the average peak Clinical Institute Withdrawal Assessment for Alcohol Scale, revised score measured over the treatment period (minimum score = 0; maximum score = 67; higher score indicates greater withdrawal severity).
| score on a scale | Symptom-triggered Diazepam Treatment |
|---|---|
| Day 1 | 12.1 ± 4.3 |
| Day 2 | 9.4 ± 4.7 |
| Day 3 | 6.6 ± 4.2 |
Collected over The adverse events reported were collected throughout the withdrawal treatment phase of the study (Detox day 1-3). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symptom-triggered Diazepam Treatment | 0/30 (0%) | 0/30 (0%) | 22/30 (73.3%) |
| Event | Symptom-triggered Diazepam Treatment |
|---|---|
| SedationNervous system disorders | 19/30 |
| ClumsinessNervous system disorders | 5/30 |
| Memory LossNervous system disorders | 3/30 |
| Light-headednessNervous system disorders | 3/30 |
| DizzinessNervous system disorders | 3/30 |
| Leg WeaknessMusculoskeletal and connective tissue disorders | 3/30 |
| HypertensionCardiac disorders | 1/30 |
| ConfusionNervous system disorders | 0/30 |
| FallsNervous system disorders | 0/30 |
| SeizuresNervous system disorders | 0/30 |
| Age, Continuous(years) | Symptom-triggered Diazepam Treatment |
|---|---|
| Mean | 44.0 ± 11.3 |
| Sex: Female, Male(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| Female | 12 |
| Male | 18 |
| Race/Ethnicity, Customized(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| Ethnicity — White-European | 20 |
| Ethnicity — Other | 10 |
| Marital Status(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| Married/Common Law | 12 |
| Other | 18 |
| Income(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| > $60 000 | 15 |
| < $60,000 | 15 |
| Education(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| Higher Education Past Secondary School | 24 |
| Other | 6 |
| Prior Detoxification Experience(Participants) | Symptom-triggered Diazepam Treatment |
|---|---|
| Yes | 13 |
| No | 17 |
| Alcohol Use Disorders Identification Test (AUDIT)(units on a scale) | Symptom-triggered Diazepam Treatment |
|---|---|
| Mean | 29.9 ± 4.2 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Oct 2023, 24 months.
Results were first posted in May 2026, 2 years 6 months after primary completion.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 24 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diazepam
Centre for Addiction and Mental Health →